Skip to content

Thermal ablation of large thyroid nodules, microscopic papillary carcinoma, and multiple nodules

Thermal ablation of large thyroid nodules, microscopic papillary carcinoma, and multiple nodules: a multicentric prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019769
Enrollment
Unknown
Registered
2018-11-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thermal ablation of thyroid nodules

Interventions

Case series:Thermal ablation technique

Sponsors

Affiliated Hospital of Jiangsu University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Benign thyroid nodules (maximum diameter > 4cm): (1) preoperative fine needle biopsy pathology FNA cytology - Bethesda report system for II class (at least twice), or a FNA inspection and typical benign nodules ultrasonic ultrasonographic, or preoperative histological pathology confirmed benign nodules; (2) the maximum diameter of the nodules was greater than 4cm, and located in the thyroid gland lobe; (3) the patient has no history of childhood radiotherapy; (4) the patient has obvious nodules and related conscious symptoms (such as foreign body sensation, neck discomfort or pain, etc.) or affect the aesthetic, require treatment; (5) patients with full knowledge of the situation requires minimally invasive interventional therapy, or refuse surgery and clinical observation; 6) residual recurrence of nodules after surgery, and nodules volume increased significantly. 2. Thyroid micropapillary carcinoma (PTMC) The following conditions shall be met simultaneously and medical ethics shall be strictly observed, especially when patients are fully informed: (1) non-pathological non-pathological high-risk subtype; (2) it is recommended to select the tumor diameter less than 5mm (for those who do not adhere to the capsule around the tumor, the diameter can be expanded to less than 1cm), and the nodule is 2mm away from the inner posterior capsule >; (3) no thyroid membrane invasion and no peripheral tissue invasion; (4) cancer focus is not located in the isthmus; (5) no family history of thyroid cancer; 6. No history of neck radiation exposure during adolescence or childhood; 7) no evidence of lymph nodes or distant metastasis; 8) patients who refuse surgery or close follow-up even after being fully informed by medical staff; 9) primary treatment. 3. Multiple thyroid nodules (1) preoperative multiple nodules are similar to the very low or low malignant risk, puncture the largest nodules, pathologically confirmed as benign nodules; (2) the maximum diameter of nodules located in the isthmus was less than 2cm; (3) the patient has no history of childhood radiotherapy; (4) the patient has obvious nodules and related conscious symptoms (such as foreign body sensation, neck discomfort or pain, etc.) or affect the aesthetic, require treatment; (5) patients with full knowledge of the situation requires minimally invasive interventional therapy, or refuse surgery and clinical observation.

Exclusion criteria

Exclusion criteria: 1. Contralateral vocal cord dysfunction; 2. Serious blood coagulation disorders; 3. Important viscera function is not complete; 4. Pregnant women. 5. Benign thyroid nodules (maximum diameter > 4cm): (1) large retrosternal goiter or most thyroid nodules are located behind the sternum; (2) with coarse calcification. 6. Thyroid micropapillary carcinoma (PTMC): (1) have done surgical treatment; (2) neck or distant metastasis; (3) the cancer lesion progressively increased within a short period of time (increased by more than 3mm within 6 months); (4) pathological high-risk subtype (high cell subtype, columnar cell subtype, diffuse sclerosis type, solid/island type, eosinophilic subtype); 7. Multiple nodules: (1) large retrosternal goiter or most thyroid nodules are located behind the sternum; (2) have done surgical treatment.

Design outcomes

Primary

MeasureTime frame
Nodule size;

Countries

China

Contacts

Public ContactBaoding Chen

Affiliated Hospital of Jiangsu University

alphalife@163.com+86 13511696205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026